A useful research claim answers five questions: who was studied, what was compared, how much was given, for how long, and what was measured. Use this guide alongside any ingredient page to reconstruct that chain before interpreting the result.
Key points
When reading results, check who was studied, the comparator and duration, as well as what changed. Distinguish single-ingredient findings from testing of multi-ingredient products.
Scientific Evidence Profile · How we assess evidence
We assess a defined outcome in a defined population, with formulation, dose and duration recorded. These editorial categories describe confidence in the stated evidence, not effect size or a recommendation. They are not formal GRADE ratings. Article publication-quality grades are a separate assessment.
- Strong
- Consistent, precise findings from multiple independent, well-conducted human studies directly addressing the stated outcome, with no major unresolved bias.
- Moderate
- Human studies directly address the outcome and provide replicated support, but an important limitation in precision, consistency or study methods remains.
- Limited
- Human intervention findings are available, but small samples, exploratory outcomes, inconsistent findings or incomplete independent replication materially limit confidence.
- Very limited
- Evidence for the stated human benefit is indirect or primarily exploratory, with major limitations; mechanisms alone cannot establish a clinical benefit.
- Assessment pending
- An outcome-specific assessment has not yet been completed. This is not a finding that the ingredient is ineffective. The study records below remain available.
Record the question, comparable human studies, important contradictory findings, search date and source-review scope. Assess bias, sample size and precision, independent replication, consistency and directness to the outcome. Separate biomarkers from patient-important outcomes. A review does not automatically raise the level; inspect its methods and the underlying trials. Funding alone does not lower the level, but sponsor roles and selective reporting matter. Positive-first presentation is not a deduction. Use the highest category whose conditions are supported and explain the limiting domain; do not average domain scores. If essential information is missing, leave the assessment pending. A second editorial check is required before scaling beyond this pilot.
- Human study quality
- Allocation, blinding, attrition, prespecification and analysis.
- Scale and replication
- Participants, uncertainty of estimates and independent comparable trials; not paper count alone.
- Consistency of findings
- Agreement across comparable outcomes, populations and formulations.
- Clinical relevance
- Biomarker, subjective score, functional change or clinical event; strength is specific to that endpoint.
- Systematic reviews / meta-analyses
- Availability, relevance and methods of systematic reviews or meta-analyses.
- Limitations / funding / COI
- Generalizability, reporting gaps, funding and author conflicts; unknown is not none.
Editorial pilot · selected evidence; not a systematic review or formal GRADE assessment.
This profile concerns the stated outcome and population, not the ingredient as a whole. It is not a probability of benefit, a safety rating, a product efficacy rating or an indication of product adoption.
Profile reviewed: 2026-10-25 · v1.0
GRADE Working Group: outcome-specific certainty · Cochrane Handbook, Chapter 14
First, identify the research question #
Studies of the same ingredient can answer different questions: absorption is not the same as symptoms or physical function. “Studied in humans” alone does not tell you what is known.
LÍFSVARÐA lists populations, comparators, durations and outcomes for each study. The aim is not a single score, but to show how closely the evidence matches your question.
Distinguish biomarker changes from health benefits #
Biomarkers measured in blood or elsewhere describe biological states or responses. Changes alone do not necessarily demonstrate symptom improvement or lifespan benefit. Use as a surrogate predicting clinical benefit requires validation for the intended purpose.[1]
For example, a rise in blood concentration initially provides information about absorption. It should not be extended into conclusions about disease prevention or slower aging.
Read findings alongside populations and conditions #
Research in one age group or health condition cannot apply to everyone. Dose, chemical form, duration and concurrent treatment all inform interpretation.
Commercial products can differ from study products in important ways.[2] A shared ingredient name does not establish that the same results will follow.
Distinguish ingredient research from product research #
Interpret each study within its own intervention and population; an ingredient study is not a test of a different finished formulation.
Claims about finished-product effects require testing relevant to that product. Combining ingredients or disclosing their amounts alone does not establish efficacy.
Our Knowledge editorial policy #
We organize information from primary studies and official sources. Ingredient articles explain selected papers; they are not systematic reviews of all research. English is the editorial source for the Japanese and Vietnamese editions.
Each article lists sources, review dates and editorial responsibility. New information that changes conclusions, or identified errors, will prompt updates to the text and revision history. Articles are not intended for individual diagnosis, treatment or dosage instructions.
LITERATURE MAP / 10 PAPERS
Compare papers by conditions and findings.
A literature map exploring this topic from different angles. It includes observational studies, research frameworks and methodology as well as intervention trials, with the study type indicated.
Selected: 2026-09-21. Bibliographic information checked against Europe PMC / PubMed. Editorial selection considered major papers and a range of populations and questions. This is not a systematic search covering all recent research.
10 RECORDS
A dash marks fields outside the bibliographic record. Use detailed records to compare findings and design records to connect mechanisms.
No papers match. Change the search conditions.
The literature map is an index of research questions and references. Individual assessment of results, doses, funding and COI is limited to the detailed study records. Related reports from the same trial may be included; paper counts are not counts of independent trials.
Cite this page
LÍFSVARÐA. How to read “shown in research.” Version 3.1 / Updated 2026-10-24
https://lifsvarda.com/knowledge/reading-evidence/Edited by LÍFSVARÐA (product brand).Editorial policy
Sources and updates
- FDA: biomarkers and surrogate endpointsOfficial explanation
- NCCIH: using dietary supplements wiselyOfficial explanation
First published: 2026-09-20 / Version 3.1. Updated 2026-09-23: Added a research comparison table and links to design records. Source notes identify the scope of verification when the full paper has not been reviewed. Research summaries and LÍFSVARÐA’s interpretation are distinguished.